Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Clinical trial NCT05545124 · UNKNOWN
Trial details
- NCT number
- NCT05545124
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-01
- Primary completion
- 2023-11-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.